Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.
Wave will soon report key early-stage data with its exon-skipping DMD candidate suvodirsen but, unlike Sarepta, the group is starting its confirmatory trial before…
Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.